C.E.R.A. Anti-Anemia Drug Maintained Stable Hemoglobin Levels In Dialysis Patients With Up To Once Every 4 Week Dosing In Phase III Clinical Studies

... Dialysis patients treated with short-acting and frequently administered epoetin were switched to a once every two week or once every four week treatment and maintained stable hemoglobin (Hb) levels, according to data presented today.1,2 This new treatment is Roche's investigational Continuous Erythropoietin Receptor Activator (C.E.R.A. [click link for full article] ...